Synergy jumps on plecanatide constipation data

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) added $0.95 (18%) to $6.21 on Wednesday after once-daily 3 mg oral plecanatide met the primary endpoint in the Phase IIb/III SP304-20210 trial to treat chron...